Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
173 hedge funds and large institutions have $3.11B invested in Cidara Therapeutics in 2025 Q3 according to their latest regulatory filings, with 77 funds opening new positions, 51 increasing their positions, 30 reducing their positions, and 13 closing their positions.
492% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 13
146% more capital invested
Capital invested by funds: $1.26B → $3.11B (+$1.85B)
70% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 30
59% more funds holding
Funds holding: 109 → 173 (+64)
56% more funds holding in top 10
Funds holding in top 10: 9 → 14 (+5)
6.8% more ownership
Funds ownership: 121.35% → 128.16% (+6.8%)
27% less call options, than puts
Call options by funds: $52.4M | Put options by funds: $71.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$61.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$40.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$34.2M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$33.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$49M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$41.5M |
| 3 |
CC
Commodore Capital
New York
|
-$37.6M |
| 4 |
Morgan Stanley
New York
|
-$32.2M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$15.2M |
CDTX Hedge Fund Activity: Q3 2025 in Review
173 of the 7,635 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2025, worth a combined $3.11B — up 146% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new CDTX positions and 13 closed out — a net gain of 64 holders — while 51 added to existing stakes and 30 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $61.3M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $49M sold.
- 173 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2025, up from 109 in Q2 2025.
- Funds reported $3.11B of Cidara Therapeutics stock for Q3 2025, up 146% quarter-over-quarter.
- 77 funds opened new Cidara Therapeutics positions in Q3 2025 and 13 closed out, a net change of +64 holders.
- The largest Cidara Therapeutics buyer in Q3 2025 was Paradigm Biocapital Advisors, an estimated $61.3M added.
- The largest Cidara Therapeutics seller in Q3 2025 was TCG Crossover Management, an estimated $49M sold.
Based on aggregated 13F filings for Q3 2025.